137 related articles for article (PubMed ID: 12729388)
1. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations.
Mallinckrodt CH; Clark SW; Carroll RJ; Molenbergh G
J Biopharm Stat; 2003 May; 13(2):179-90. PubMed ID: 12729388
[TBL] [Abstract][Full Text] [Related]
2. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
Siddiqui O; Hung HM; O'Neill R
J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
[TBL] [Abstract][Full Text] [Related]
3. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA.
Mallinckrodt CH; Kaiser CJ; Watkin JG; Molenberghs G; Carroll RJ
Clin Trials; 2004; 1(6):477-89. PubMed ID: 16279288
[TBL] [Abstract][Full Text] [Related]
4. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.
Siddiqui O
J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
[TBL] [Abstract][Full Text] [Related]
6. An overview of practical approaches for handling missing data in clinical trials.
DeSouza CM; Legedza AT; Sankoh AJ
J Biopharm Stat; 2009 Nov; 19(6):1055-73. PubMed ID: 20183464
[TBL] [Abstract][Full Text] [Related]
7. Accounting for dropout bias using mixed-effects models.
Mallinckrodt CH; Clark WS; David SR
J Biopharm Stat; 2001; 11(1-2):9-21. PubMed ID: 11459446
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts.
Siddiqui O; Ali MW
J Biopharm Stat; 1998 Nov; 8(4):545-63. PubMed ID: 9855033
[TBL] [Abstract][Full Text] [Related]
9. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.
Lane P
Pharm Stat; 2008; 7(2):93-106. PubMed ID: 17351897
[TBL] [Abstract][Full Text] [Related]
10. Marginal analysis of incomplete longitudinal binary data: a cautionary note on LOCF imputation.
Cook RJ; Zeng L; Yi GY
Biometrics; 2004 Sep; 60(3):820-8. PubMed ID: 15339307
[TBL] [Abstract][Full Text] [Related]
11. Analyzing incomplete longitudinal clinical trial data.
Molenberghs G; Thijs H; Jansen I; Beunckens C; Kenward MG; Mallinckrodt C; Carroll RJ
Biostatistics; 2004 Jul; 5(3):445-64. PubMed ID: 15208205
[TBL] [Abstract][Full Text] [Related]
12. Impact of missing data on type 1 error rates in non-inferiority trials.
Yoo B
Pharm Stat; 2010; 9(2):87-99. PubMed ID: 19408241
[TBL] [Abstract][Full Text] [Related]
13. Analysis of longitudinal binary data with missing data due to dropouts.
Ali MW; Talukder E
J Biopharm Stat; 2005; 15(6):993-1007. PubMed ID: 16279357
[TBL] [Abstract][Full Text] [Related]
14. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.
Mallinckrodt CH; Sanger TM; Dubé S; DeBrota DJ; Molenberghs G; Carroll RJ; Potter WZ; Tollefson GD
Biol Psychiatry; 2003 Apr; 53(8):754-60. PubMed ID: 12706959
[TBL] [Abstract][Full Text] [Related]
15. Semi-parametric and non-parametric methods for clinical trials with incomplete data.
O'Brien PC; Zhang D; Bailey KR
Stat Med; 2005 Feb; 24(3):341-58. PubMed ID: 15547952
[TBL] [Abstract][Full Text] [Related]
16. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
Salim A; Mackinnon A; Christensen H; Griffiths K
Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
[TBL] [Abstract][Full Text] [Related]
17. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods.
Houck PR; Mazumdar S; Koru-Sengul T; Tang G; Mulsant BH; Pollock BG; Reynolds CF
Psychiatry Res; 2004 Dec; 129(2):209-15. PubMed ID: 15590048
[TBL] [Abstract][Full Text] [Related]
18. The impact of missing data and how it is handled on the rate of false-positive results in drug development.
Barnes SA; Mallinckrodt CH; Lindborg SR; Carter MK
Pharm Stat; 2008; 7(3):215-25. PubMed ID: 17853425
[TBL] [Abstract][Full Text] [Related]
19. A local influence sensitivity analysis for incomplete longitudinal depression data.
Shen S; Beunckens C; Mallinckrodt C; Molenberghs G
J Biopharm Stat; 2006 May; 16(3):365-84. PubMed ID: 16724491
[TBL] [Abstract][Full Text] [Related]
20. Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome.
Hall SM; Delucchi KL; Velicer WF; Kahler CW; Ranger-Moore J; Hedeker D; Tsoh JY; Niaura R
Nicotine Tob Res; 2001 Aug; 3(3):193-202. PubMed ID: 11506764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
